A Phase 3, Multicenter, Randomized, Double-Blind, Parallel,
Placebo-Controlled Induction Study of Mirikizumab in
Conventional-Failed and Biologic-Failed Patients with Moderately to
Severely Active Ulcerative Colitis (Protocol I6T-MC-AMAN/LUCENT
1)
Please contact us for more information or to learn if you are eligible to participate.
